v3.22.4
Collaboration, Licensing and Other Arrangements - Revenue Allocation (Detail) - USD ($)
$ in Millions
 1 Months Ended 12 Months Ended
Oct. 31, 2021
Oct. 16, 2021
Apr. 30, 2022
Dec. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Total transaction price $ 50.9      
R&D Services and License | Over Time        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Total transaction price [1] $ 18.4      
Progress Measure Ratably      
Recognition Period [2] May 2021 - Oct 2021      
Pre-Commercial Services | Over Time        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Total transaction price [1] $ 4.6      
Progress Measure Input      
Recognition Period [3] % of completion of costs      
Next-Gen R&D Services | Over Time        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Total transaction price [1] $ 7.2      
Progress Measure Input      
Recognition Period [3] % of completion of costs      
Facility Expansion Services | Point In Time        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Total transaction price [1],[4] $ 20.7      
Recognition Period [4],[5] Transfer of control      
Collaboration and License Agreement | United Therapeutics Corporation        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Total transaction price       $ 50.9
Collaboration and License Agreement | R&D Services and License | United Therapeutics Corporation | Over Time        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Progress Measure [6]   Ratably Ratably Ratably
Recognition Period [6],[7]   Aug 2021 - Oct 2021 Aug 2021 - Oct 2021 Aug 2021 - Oct 2021
Collaboration and License Agreement | Next-Gen R&D Services | United Therapeutics Corporation | Over Time        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Total transaction price [1],[8]   $ 4.8 $ 5.9 $ 10.0
Progress Measure [8]   Input Input Input
Recognition Period [8],[9]   % of completion of costs % of completion of costs % of completion of costs
Clinical Supplies | Collaboration and License Agreement | United Therapeutics Corporation        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Total transaction price       $ 105.8
Clinical Supplies | Collaboration and License Agreement | R&D Services and License | United Therapeutics Corporation | Over Time        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Total transaction price       $ 105.8
Allocation of Price       100.00%
Progress Measure       Ratably
Recognition Period [10]       Sep 2018 - Dec 2021
[1]

Allocation is based on management’s assessment of the stand-alone selling price of each performance obligation.
[2]

Represents the estimated period when the R&D Services performance obligation will be substantially complete.
[3]

Pre-Commercial Services and Next-Gen R&D Services performance obligations will be satisfied over time using the input method based on the costs incurred to date as a percentage of the total estimated costs to fulfill the contract. Incurred cost represents work performed, which corresponds with, and thereby best depicts, the transfer of control to the customer.
[4]

The Company also acts as agent for the procurement of equipment for the manufacturing expansion for the UT Equipment. The Company received $5.0 million from UT for the UT Equipment, which was recognized as deposits from customer on the consolidated balance sheet and will be released as the title is transferred to UT.
[5]

The Facility Expansion Services performance obligation would be recognized as control of manufactured products is transferred to the customer.
[6]

The license for the Company’s IP was considered to be interdependent with the development activities to support approval of Tyvaso DPI. A sales-based royalty is promised in exchange for the IP license; therefore, the royalties associated with the license are excluded from the determination of the transaction price and the Company will recognize revenue as the sale of Tyvaso DPI to a patient occurs.

[7]

Represents the period when the revenue for the R&D Services performance obligation was recognized.
[8]

The standalone selling price (“SSP”) for the Next-Gen R&D Services performance obligation was based on industry ratios as well as the Company’s historical R&D projects. The transaction price for the Next-Gen R&D Services was based on fixed consideration which was allocated between performance obligations as discussed in note (2) above.
[9]

The Next-Gen R&D Services performance obligation will be satisfied over time using the input method based on the costs incurred to date as a percentage of the total estimated costs to fulfill the contract. Incurred cost represents work performed, which corresponds with, and thereby best depicts, the transfer of control to the customer.
[10]

Recognition period represents the estimated period to satisfy the performance obligation.